according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: **HP66** Version: **3.0 en** Replaces version of: 2022-08-15 Version: (2)

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier

Identification of the substance

Article number

Registration number (REACH)

Streptomycin sulphate CELLPURE® ≥720 I.U./ mg

HP66

223-286-0

It is not required to list the identified uses because the substance is not subject to registration according to REACH (< 1 t/a).

EC number CAS number

3810-74-0

1.2 Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses:

Uses advised against:

Laboratory chemical Laboratory and analytical use

Do not use for products which come into contact with foodstuffs. Do not use for private purposes (household). Food, drink and animal feedingstuffs.

1.3 Details of the supplier of the safety data sheet

Carl Roth GmbH + Co. KG Schoemperlenstr. 3-5 D-76185 Karlsruhe Germany

Telephone:+49 (0) 721 - 56 06 0 **Telefax:** +49 (0) 721 - 56 06 149 **e-mail:** sicherheit@carlroth.de **Website:** www.carlroth.de

Competent person responsible for the safety data Department Health, Safety and Environment sheet:

e-mail (competent person):

sicherheit@carlroth.de

1.4 Emergency telephone number

Name	Street	Postal code/city	Telephone	Website
National Poisons Information Centre Beaumont Hospital	Beaumont Road	Dublin 9	+353 1 809 2166	https:// www.poisons.ie/

date of compilation: 2019-07-25 Revision: 2024-03-02

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No 1272/2008 (CLP)

Section	Hazard class		Hazard class and category	Hazard statement
3.10	Acute toxicity (oral)	4	Acute Tox. 4	H302
3.7	Reproductive toxicity	2	Repr. 2	H361d

For full text of abbreviations: see SECTION 16

2.2 Label elements

Labelling according to Regulation (EC) No 1272/2008 (CLP)

Signal word Warning

Pictograms

GHS07, GHS08



Hazard statements

H302Harmful if swallowedH361dSuspected of damaging the unborn child

Precautionary statements

Precautionary statements - prevention

P280 Wear protective clothing/eye protection

Precautionary statements - response

P301+P312	IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell
P308+P313	IF exposed or concerned: Get medical advice/attention

For professional users only

Labelling of packages where the contents do not exceed 125 ml

Signal word: Warning

Symbol(s)



H361dSuspected of damaging the unborn child.P280Wear protective clothing/eye protection.P308+P313IF exposed or concerned: Get medical advice/attention.

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

2.3 Other hazards

Results of PBT and vPvB assessment

According to the results of its assessment, this substance is not a PBT or a vPvB.

Endocrine disrupting properties

Does not contain an endocrine disruptor (ED) at a concentration of $\ge 0,1\%$.

SECTION 3: Composition/information on ingredients

3.1 Substances

Name of substance	Streptomycin sulphate
Molecular formula	$C_{42}H_{84}N_{14}O_{36}S_3$
Molar mass	1.457 ^g / _{mol}
CAS No	3810-74-0
EC No	223-286-0

Substance, Specific Conc. Limits, M-factors, ATE

Specific Conc. Limits	M-Factors	ATE	Exposure route
-	-	430 ^{mg} / _{kg}	oral

SECTION 4: First aid measures

4.1 Description of first aid measures



General notes

Take off contaminated clothing.

Following inhalation

Provide fresh air. In all cases of doubt, or when symptoms persist, seek medical advice.

Following skin contact

Rinse skin with water/shower.

Following eye contact

Rinse cautiously with water for several minutes.

Following ingestion

Rinse mouth with water (only if the person is conscious). In case of accident or unwellness, seek medical advice immediately (show directions for use or safety data sheet if possible). Call a doctor.

4.2 Most important symptoms and effects, both acute and delayed

Vomiting, Malaise, Nausea

4.3 Indication of any immediate medical attention and special treatment needed

none

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU

Streptomycin sulphate CELLPURE® ≥720 I.U./mg



article number: HP66

SECTION 5: Firefighting measures

5.1 Extinguishing media



Suitable extinguishing media

co-ordinate firefighting measures to the fire surroundings! water, foam, dry extinguishing powder, ABC-powder

Unsuitable extinguishing media

water jet

5.2 Special hazards arising from the substance or mixture

Combustible.

Hazardous combustion products

In case of fire may be liberated: Nitrogen oxides (NOx), Carbon monoxide (CO), Carbon dioxide (CO₂), Sulphur oxides (SOx)

5.3 Advice for firefighters

In case of fire and/or explosion do not breathe fumes. Fight fire with normal precautions from a reasonable distance. Wear self-contained breathing apparatus.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures



For non-emergency personnel

Use personal protective equipment as required. Avoid contact with skin, eyes and clothes. Do not breathe dust.

6.2 Environmental precautions

Keep away from drains, surface and ground water. Retain contaminated washing water and dispose of it.

6.3 Methods and material for containment and cleaning up

Advice on how to contain a spill

Covering of drains. Take up mechanically.

Advice on how to clean up a spill

Take up mechanically. Control of dust.

Other information relating to spills and releases

Place in appropriate containers for disposal.

6.4 Reference to other sections

Hazardous combustion products: see section 5. Personal protective equipment: see section 8. Incompatible materials: see section 10. Disposal considerations: see section 13.

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Avoid exposure. Avoid dust formation.

Measures to prevent fire as well as aerosol and dust generation

Removal of dust deposits.

Advice on general occupational hygiene

Wash hands before breaks and after work. Keep away from food, drink and animal feedingstuffs.

7.2 Conditions for safe storage, including any incompatibilities

Store in a dry place.

Incompatible substances or mixtures

Observe hints for combined storage.

Consideration of other advice:

Ventilation requirements

Use local and general ventilation.

Specific designs for storage rooms or vessels

Recommended storage temperature: 15 - 25 °C

7.3 Specific end use(s)

No information available.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

National limit values

Occupational exposure limit values (Workplace Exposure Limits)

Coun try	Name of agent	CAS No	Identifi- er	TWA [mg/ m³]	STEL [mg/ m³]	Ceil- ing-C [mg/ m ³]	Nota- tion	Source
IE	dusts, non-specific		OELV	10			i	S.I. No. 619 of 2001
IE	dusts, non-specific		OELV	4			r	S.I. No. 619 of 2001

Notation

Ceiling-C Ceiling value is a limit value above which exposure should not occur

Inhalable fraction Respirable fraction

STEL Short-term exposure limit: a limit value above which exposure should not occur and which is related to a 15minute period (unless otherwise specified)

TWA Time-weighted average (long-term exposure limit): measured or calculated in relation to a reference period of 8 hours time-weighted average (unless otherwise specified)

8.2 Exposure controls

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU

Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

Individual protection measures (personal protective equipment)

Eye/face protection

Use safety goggle with side protection.

Skin protection



hand protection

Wear suitable gloves. Chemical protection gloves are suitable, which are tested according to EN 374. For special purposes, it is recommended to check the resistance to chemicals of the protective gloves mentioned above together with the supplier of these gloves. The times are approximate values from measurements at 22 ° C and permanent contact. Increased temperatures due to heated substances, body heat etc. and a reduction of the effective layer thickness by stretching can lead to a consider-able reduction of the breakthrough time. If in doubt, contact manufacturer. At an approx. 1.5 times larger / smaller layer thickness, the respective breakthrough time is doubled / halved. The data apply only to the pure substance. When transferred to substance mixtures, they may only be considered as a guide.

• type of material

NBR (Nitrile rubber)

material thickness

>0,11 mm

• breakthrough times of the glove material

>480 minutes (permeation: level 6)

other protection measures

Take recovery periods for skin regeneration. Preventive skin protection (barrier creams/ointments) is recommended.

Respiratory protection



Respiratory protection necessary at: Dust formation. Particulate filter device (EN 143). P2 (filters at least 94 % of airborne particles, colour code: White).

Environmental exposure controls

Keep away from drains, surface and ground water.



according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU

Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

SECTION 9: Physical and chemical properties

9.1	Information on basic physical and chemical pro	perties
	Physical state	solid
	Form	powder
	Colour	whitish
	Odour	odourless
	Melting point/freezing point	not determined
	Boiling point or initial boiling point and boiling range	not determined
	Flammability	this material is combustible, but will not ignite readily
	Lower and upper explosion limit	not determined
	Flash point	not applicable
	Auto-ignition temperature	not determined
	Decomposition temperature	not relevant
	pH (value)	4,5 – 7 (in aqueous solution: 50 ^g / _l , 20 °C)
	Kinematic viscosity	not relevant
	Solubility(ies)	
	Water solubility	(soluble)
	Partition coefficient	
	Partition coefficient n-octanol/water (log value):	this information is not available
	Vapour pressure	not determined
	Density and/or relative density	
	Density	not determined
	Relative vapour density	Information on this property is not available.
	Bulk density	400 – 600 ^{kg} / _{m³}
	Particle characteristics	No data available.
	Other safety parameters	
	Oxidising properties	none
9.2	Other information	
	Information with regard to physical hazard classes:	hazard classes acc. to GHS (physical hazards): not relevant
	Other safety characteristics:	There is no additional information.



according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

SECTION 10: Stability and reactivity

10.1 Reactivity

The product in the delivered form is not dust explosion capable; the enrichment of fine dust however leads to the danger of dust explosion.

10.2 Chemical stability

The material is stable under normal ambient and anticipated storage and handling conditions of temperature and pressure.

10.3 Possibility of hazardous reactions

Violent reaction with: strong oxidiser

- **10.4 Conditions to avoid** Protect from moisture.
- 10.5 Incompatible materials

There is no additional information.

10.6 Hazardous decomposition products

Hazardous combustion products: see section 5.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Classification according to GHS (1272/2008/EC, CLP)

Acute toxicity

Harmful if swallowed.

Acute toxicity

Exposure route	Endpoint	Value	Species	Method	Source
oral	LD50	430 ^{mg} / _{kg}	rat		

Skin corrosion/irritation

Shall not be classified as corrosive/irritant to skin.

Serious eye damage/eye irritation

Shall not be classified as seriously damaging to the eye or eye irritant.

Respiratory or skin sensitisation

Shall not be classified as a respiratory or skin sensitiser.

Germ cell mutagenicity

Shall not be classified as germ cell mutagenic.

Carcinogenicity

Shall not be classified as carcinogenic.

Reproductive toxicity

Suspected of damaging the unborn child.

Specific target organ toxicity - single exposure

Shall not be classified as a specific target organ toxicant (single exposure).

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

Specific target organ toxicity - repeated exposure

Shall not be classified as a specific target organ toxicant (repeated exposure).

Aspiration hazard

Shall not be classified as presenting an aspiration hazard.

Symptoms related to the physical, chemical and toxicological characteristics

• If swallowed

vomiting, nausea, malaise

• If in eyes

Data are not available.

• If inhaled

Data are not available.

• If on skin

Data are not available.

• Other information

none

11.2 Endocrine disrupting properties

Does not contain an endocrine disruptor (ED) at a concentration of $\ge 0,1\%$.

11.3 Information on other hazards

There is no additional information.

SECTION 12: Ecological information

12.1 Toxicity

Shall not be classified as hazardous to the aquatic environment.

Aquatic toxicity (acute)						
Endpoint	Value	Species	Source	Exposure time		
EC50	650 ^{mg} / _l	daphnia magna		48 h		
LC50	>180 ^{mg} / _l	rainbow trout (Onco- rhynchus mykiss)		96 h		

12.2 Persistence and degradability

Theoretical Oxygen Demand (without nitrification): 0,8563 $^{mg}/_{mg}$ Theoretical Oxygen Demand (with nitrification): 1,089 $^{mg}/_{mg}$ Theoretical Carbon Dioxide: 1,268 $^{mg}/_{mg}$

12.3 Bioaccumulative potential

Data are not available.

12.4 Mobility in soil

Data are not available.

12.5 Results of PBT and vPvB assessment

Data are not available.

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

12.6 Endocrine disrupting properties

Does not contain an endocrine disruptor (ED) at a concentration of $\ge 0,1\%$.

12.7 Other adverse effects

Data are not available.

SECTION 13: Disposal considerations

13.1 Waste treatment methods



This material and its container must be disposed of as hazardous waste. Dispose of contents/container in accordance with local/regional/national/international regulations.

Sewage disposal-relevant information

Do not empty into drains.

Waste treatment of containers/packagings

Handle contaminated packages in the same way as the substance itself. Completely emptied packages can be recycled.

13.2 Relevant provisions relating to waste

The allocation of waste identity numbers/waste descriptions must be carried out according to the EEC, specific to the industry and process.

Properties of waste which render it hazardous

HP 6 acute toxicityHP 10 toxic for reproduction

13.3 Remarks

Waste shall be separated into the categories that can be handled separately by the local or national waste management facilities. Please consider the relevant national or regional provisions. Non-contaminated packages may be recycled.

SECTION 14: Transport information 14.1 UN number or ID number not subject to transport regulations 14.2 UN proper shipping name not assigned 14.3 Transport hazard class(es) none 14.4 Packing group not assigned 14.5 Environmental hazards non-environmentally hazardous acc. to the dangerous goods regulations 14.6

.6 Special precautions for user There is no additional information.

14.7 Maritime transport in bulk according to IMO instruments

The cargo is not intended to be carried in bulk.

14.8 Information for each of the UN Model Regulations

International Maritime Dangerous Goods Code (IMDG) - Additional information Not subject to IMDG.

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

International Civil Aviation Organization (ICAO-IATA/DGR) - Additional information

Not subject to ICAO-IATA.

SECTION 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture 15.1

Relevant provisions of the European Union (EU)

Restrictions according to REACH, Annex XVII

Dangerous substances with restrictions (REACH, Annex XVII)						
Name of substance	Name acc. to inventory	CAS No	Restriction	Νο		
Streptomycin sulphate	substances in tattoo inks and perman- ent make-up		R75	75		

Leaend

R75

1. Shall not be placed on the market in mixtures for use for tattooing purposes, and mixtures containing any such sub-stances shall not be used for tattooing purposes, after 4 January 2022 if the substance or substances in question is or are present in the following circumstances:

(a) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as carcinogen category 1A, 1B or 2, or germ cell mutagen category 1A, 1B or 2, the substance is present in the mixture in a concentration equal to or greater than 0,00005 % by weight;
(b) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as reproductive toxicant

category 1A, 1B or 2, the substance is present in the mixture in a concentration equal to or greater than 0,001 % by weight;

(c) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as skin sensitiser cat-egory 1, 1A or 1B, the substance is present in the mixture in a concentration equal to or greater than 0,001 % by weight;

(d) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as skin corrosive category 1, 1A, 1B or 1C or skin irritant category 2, or as serious eye damage category 1 or eye irritant category 2, the substance is present in the mixture in a concentration equal to or greater than:

(i) 0,1 % by weight, if the substance is used solely as a pH regulator;
(ii) 0,1 % by weight, in all other cases;
(e) in the case of a substance listed in Annex II to Regulation (EC) No 1223/2009 (*1), the substance is present in the mixture in a concentration equal to or greater than 0,00005 % by weight;
(f) in the case of a substance for which a condition of one or more of the following kinds is specified in column g (Product type, Body parts) of the table in Annex IV to Regulation (EC) No 1223/2009, the substance is present in the mixture in a concentration equal to or greater than 0,0005 % by weight; mixture in a concentration equal to or greater than 0,00005 % by weight:

(i) "Rinse-off products";
 (ii) "Not to be used in products applied on mucous membranes";

(iii) "Not to be used in eye products"; (g) in the case of a substance for which a condition is specified in column h (Maximum concentration in ready for use preparation) or column i (Other) of the table in Annex IV to Regulation (EC) No 1223/2009, the substance is present in the mixture in a concentration, or in some other way, that does not accord with the condition specified in that column; (h) in the case of a substance listed in Appendix 13 to this Annex, the substance is present in the mixture in a concen-tration equal to or greater than the concentration limit specified for that substance in that Appendix. 2. For the purposes of this entry use of a mixture "for tattooing purposes" means injection or introduction of the mix-ture into a person's skin, mucous membrane or eyeball, by any process or procedure (including procedures com-monly referred to as permanent make-up, cosmetic tattooing, micro-blading and micro-pigmentation), with the aim of

making a mark or design on his or her body

making a mark or design on his or her body.
3. If a substance not listed in Appendix 13 falls within more than one of points (a) to (g) of paragraph 1, the strictest concentration limit laid down in the points in question shall apply to that substance. If a substance listed in Appendix 13 also falls within one or more of points (a) to (g) of paragraph 1, the concentration limit laid down in point (h) of paragraph 1 shall apply to that substance.
4. By way of derogation, paragraph 1 shall not apply to the following substances until 4 January 2023: (a) Pigment Blue 15:3 (CI 74160, EC No 205-685-1, CAS No 147-14-8); (b) Pigment Green 7 (CI 74260, EC No 215-524-7, CAS No 1328-53-6).
5. If Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended after 4 January 2021 to classify or re-classify a substance such that the substance then becomes caught by point (a). (b). (c) or (d) of paragraph 1 of this entry, or such

5. If Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended after 4 January 2021 to classify or re-classify a substance such that the substance then becomes caught by point (a), (b), (c) or (d) of paragraph 1 of this entry, or such that it then falls within a different one of those points from the one within which it fell previously, and the date of application of that new or revised classification is after the date referred to in paragraph 1 or, as the case may be, paragraph 4 of this entry, that amendment shall, for the purposes of applying this entry to that substance, be treated as taking effect on the date of application of that new or revised classification.
6. If Annex II or Annex IV to Regulation (EC) No 1223/2009 is amended after 4 January 2021 to list or change the listing of a substance such that the substance then becomes caught by point (e), (f) or (g) of paragraph 1 of this entry, or such that it then falls within a different one of those points from the one within which it fell previously, and the amendment shall, for the purposes of applying this entry to that substance the substance then becomes caught by point (e), (f) or (g) of paragraph 1 of this entry, or such that it then falls within a different one of those points from the one within which it fell previously, and the amendment takes effect after the date referred to in paragraph 1 or, as the case may be, paragraph 4 of this entry, that amendment shall, for the purposes of applying this entry to that substance, be treated as taking effect from the date falling 18 months after entry into force of the act by which that amendment was made.
7. Suppliers placing a mixture on the market for use for tattooing purposes shall ensure that, after 4 January 2022, the

7. Suppliers placing a mixture on the market for use for tattooing purposes shall ensure that, after 4 January 2022, the mixture is marked with the following information:
(a) the statement "Mixture for use in tattoos or permanent make-up";
(b) a reference number to uniquely identify the batch;
(c) the list of ingredients in accordance with the nomenclature established in the glossary of common ingredient name, the

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU





article number: HP66

	IUPAC name. In the absence of a common ingredient name or IUPAC name, the CAS and EC number. Ingredients sh be listed in descending order by weight or volume of the ingredients at the time of formulation. "Ingredient" means
ä	any substance added during the process of formulation and present in the mixture for use for tattooing purposes. I purities shall not be regarded as ingredients. If the name of a substance, used as ingredient within the meaning of
6	this entry, is already required to be stated on the label in accordance with Regulation (EC) No 1272/2008, that ingrec ent does not need to be marked in accordance with this Regulation;
((t	(d) the additional statement "pH regulator" for substances falling under point (d)(i) of paragraph 1; (e) the statement "Contains nickel. Can cause allergic reactions." if the mixture contains nickel below the concentra- tion limit specified in Appendix 13;
(t	(f) the statement "Contains chromium (VI). Can cause allergic reactions." if the mixture contains chromium (VI) below the concentration limit specified in Appendix 13;
((g) safety instructions for use insofar as they are not already required to be stated on the label by Regulation (EC) No 1272/2008.
1	The information shall be clearly visible, easily legible and marked in a way that is indelible. The information shall be written in the official language(s) of the Member State(s) where the mixture is placed on th market, unless the Member State(s) concerned provide(s) otherwise.
\ (Where necessary because of the size of the package, the information listed in the first subparagraph, except for poi (a), shall be included instead in the instructions for use.
F F	Before using a mixture for tattooing purposes, the person using the mixture shall provide the person undergoing the procedure with the information marked on the package or included in the instructions for use pursuant to this para graph.
ž	ð. Mixtures that do not contain the statement "Mixture for use in tattoos or permanent make-up" shall not be used f tattooing purposes.
č	9. This entry does not apply to substances that are gases at temperature of 20 °C and pressure of 101,3 kPa, or gene ate a vapour pressure of more than 300 kPa at temperature of 50 °C, with the exception of formaldehyde (CAS No 5 00-0, EC No 200-001-8).
á	10. This entry does not apply to the placing on the market of a mixture for use for tattooing purposes, or to the use a mixture for tattooing purposes, when placed on the market exclusively as a medical device or an accessory to a medical device, within the meaning of Regulation (EU) 2017/745, or when used exclusively as a medical device or an accessory to a medical device.
i	accessory to a medical device, within the same meaning. Where the placing on the market or use may not be exclus ively as a medical device or an accessory to a medical device, the requirements of Regulation (EU) 2017/745 and of t Regulation shall apply cumulatively.

Not listed.

Seveso Directive

2012/18/EU (Seveso III)

Νο	Dangerous substance/hazard categories	Qualifying quantity (tonnes) for the ap- plication of lower and upper-tier re- quirements	Notes
	not assigned		

Deco-Paint Directive

VOC con	tent	0 %

Industrial Emissions Directive (IED)

VOC content	0 %
-------------	-----

Directive on the restriction of the use of certain hazardous substances in electrical and electronic equipment (RoHS)

not listed

Regulation concerning the establishment of a European Pollutant Release and Transfer Register (PRTR)

not listed

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

ist of pollutants (WFD)				
Name of substance	Name acc. to inventory	CAS No	Listed in	Remarks
Streptomycin sulphate	Substances and preparations, or the breakdown products of such, which have been proved to pos- sess carcinogenic or mutagenic properties or properties which may affect steroidogenic, thyroid, reproduction or other endocrine- related functions in or via the aquatic environment		a)	

Legend

a) Indicative list of the main pollutants

Regulation on the marketing and use of explosives precursors

not listed

Regulation on drug precursors

not listed

Regulation on substances that deplete the ozone layer (ODS)

not listed

Regulation concerning the export and import of hazardous chemicals (PIC)

not listed

Regulation on persistent organic pollutants (POP)

not listed

Other information

Directive 94/33/EC on the protection of young people at work. Observe employment restrictions under the Maternity Protection Directive (92/85/EEC) for expectant or nursing mothers.

National inventories

Country	Inventory	Status
AU	AIIC	substance is listed
СА	DSL	substance is listed
CN	IECSC	substance is listed
EU	ECSI	substance is listed
KR	KECI	substance is listed
MX	INSQ	substance is listed
NZ	NZIoC	substance is listed
PH	PICCS	substance is listed
TW	TCSI	substance is listed
US	TSCA	substance is listed (ACTIVE)
VN	NCI	substance is listed

Legend AIIC DSL

Australian Inventory of Industrial Chemicals Domestic Substances List (DSL) according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Streptomycin sulphate CELLPURE® ≥720 I.U./mg

article number: HP66

Legend ECSI	EC Substance Inventory (EINECS, ELINCS, NLP)
IECSC INSQ	Inventory of Existing Chemical Substances Produced or Imported in China National Inventory of Chemical Substances
KECI	Korea Existing Chemicals Inventory
NCI	National Chemical Inventory
NZIOC	New Zealand Inventory of Chemicals
PICCS	Philippine Inventory of Chemicals and Chemical Substances (PICCS)
TCSI TSCA	Taiwan Chemical Substance Inventory Toxic Substance Control Act

15.2 Chemical safety assessment

No Chemical Safety Assessment has been carried out for this substance.

SECTION 16: Other information

Indication of changes (revised safety data sheet)

Section	Former entry (text/value)	Actual entry (text/value)	Safety- relev- ant
2.2		Hazard statements: change in the listing (table)	yes
2.2		Labelling of packages where the contents do not exceed 125 ml: change in the listing (table)	yes
2.3		Endocrine disrupting properties: Does not contain an endocrine disruptor (ED) at a concentration of ≥ 0,1%.	yes
14.8	Transport of dangerous goods by road, rail and inland waterway (ADR/RID/ADN) - Additional in- formation: Not subject to ADR, RID and ADN.		yes
15.1		National inventories: change in the listing (table)	yes

Abbreviations and acronyms

Abbr.	Descriptions of used abbreviations
ADR	Accord relatif au transport international des marchandises dangereuses par route (Agreement concern- ing the International Carriage of Dangerous Goods by Road)
ATE	Acute Toxicity Estimate
CAS	Chemical Abstracts Service (service that maintains the most comprehensive list of chemical substances)
Ceiling-C	Ceiling value
CLP	Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures
DGR	Dangerous Goods Regulations (see IATA/DGR)
EC50	Effective Concentration 50 %. The EC50 corresponds to the concentration of a tested substance causing 50 % changes in response (e.g. on growth) during a specified time interval
EC No	The EC Inventory (EINECS, ELINCS and the NLP-list) is the source for the seven-digit EC number, an identi- fier of substances commercially available within the EU (European Union)
ED	Endocrine disruptor
EINECS	European Inventory of Existing Commercial Chemical Substances
ELINCS	European List of Notified Chemical Substances

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU

Streptomycin sulphate CELLPURE® ≥720 I.U./mg



article number: HP66

Abbr.	Descriptions of used abbreviations
GHS	"Globally Harmonized System of Classification and Labelling of Chemicals" developed by the United Na- tions
ΙΑΤΑ	International Air Transport Association
IATA/DGR	Dangerous Goods Regulations (DGR) for the air transport (IATA)
ICAO	International Civil Aviation Organization
IMDG	International Maritime Dangerous Goods Code
LC50	Lethal Concentration 50%: the LC50 corresponds to the concentration of a tested substance causing 50 % lethality during a specified time interval
LD50	Lethal Dose 50 %: the LD50 corresponds to the dose of a tested substance causing 50 % lethality during a specified time interval
NLP	No-Longer Polymer
PBT	Persistent, Bioaccumulative and Toxic
REACH	Registration, Evaluation, Authorisation and Restriction of Chemicals
RID	Règlement concernant le transport International ferroviaire des marchandises Dangereuses (Regula- tions concerning the International carriage of Dangerous goods by Rail)
S.I. No. 619 of 2001	Safety, Health and Welfare at Work (Chemical Agents) Regulations 2001
STEL	Short-term exposure limit
SVHC	Substance of Very High Concern
TWA	Time-weighted average
VOC	Volatile Organic Compounds
vPvB	Very Persistent and very Bioaccumulative

Key literature references and sources for data

Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures. Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU.

Agreement concerning the International Carriage of Dangerous Goods by Road (ADR). Regulations concerning the International Carriage of Dangerous Goods by Rail (RID). International Maritime Dangerous Goods Code (IMDG). Dangerous Goods Regulations (DGR) for the air transport (IATA).

List of relevant phrases (code and full text as stated in section 2 and 3)

Code	Text
H302	Harmful if swallowed.
H361d	Suspected of damaging the unborn child.

Disclaimer

This information is based upon the present state of our knowledge. This SDS has been compiled and is solely intended for this product.